Recruiting

Addiction Care

Sponsor:

Michael Incze

Code:

NCT07575373

Conditions

Substance Use Disorders

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IntACT

Usual Care

Study Details

Brief summary:

The purpose of this study is to evaluate the feasibility and preliminary effectiveness of a primary care-based Interdisciplinary Addiction Care Transition (IntACT) team that will meet patients with substance use disorders (SUD) during a medical hospitalization and provide intensive care management, peer support, and interim SUD and medical care after discharge while facilitating a transition to long term community-based treatment.

Conditions

Substance Use Disorders

Study ID

NCT07575373

Start date

Jun 21, 2026

Status verified date

Aug, 2026

Completion date

Sep 15, 2027

Anticipated

Primary completion date

Sep 15, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Aged 18 years and older
  • Hospitalized at University of Utah Medical Center (UUMC) for any medical reason, and
  • Electronic Health Record (EHR) documented diagnosis of any SUD.

Exclusion Criteria:

  • Currently incarcerated
  • Tobacco use as only documented substance use disorder

Study Design

Enrollment

75 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: IntACT Intervention

Participants randomized to IntACT will receive usual inpatient and outpatient services plus an interdisciplinary addiction care transition team.

active comparator: Usual Care

Participants randomized to Usual Care will receive standard of care services routinely available at University of Utah Health.

Interventions

IntACT

Participants randomized to IntACT will receive usual inpatient and outpatient services plus an interdisciplinary addiction care transition team providing: (1) in-hospital discharge planning support, (2) proactive post-discharge outreach and care coordination, (3) intensive care management and peer support, and (4) interim SUD and medical care coordination for up to 4 months post-randomization, with the goal of facilitating transition to longitudinal community-based care.

Usual Care

Participants randomized to Usual Care will receive standard of care services routinely available at University of Utah Health, including inpatient addiction consult services when ordered, discharge planning by hospital medical and social work teams, and referrals/follow-up options based on insurance and patient preference. Usual Care participants will not receive the structured IntACT intervention components provided in the intervention arm, including proactive post-discharge outreach by the IntACT care manager/peer support specialist, intensive care management, dedicated peer navigation, scheduled interdisciplinary team review, or interim addiction/primary care transition services delivered by the IntACT team as part of the study. If a Usual Care participant independently establishes care with SPARC clinic or other services through standard referral pathways, this will be permitted and will be captured as part of outcome assessment.

Primary outcome measure

  • Care Linkage [ Time Frame: 14 Days ]
  • Retention in Treatment [ Time Frame: 6 Months ]
  • Intervention Feasibility [ Time Frame: Completed once within 2 weeks of exposure to the intervention ]
  • Intervention Acceptability [ Time Frame: Completed once within 2 weeks of exposure to the intervention ]
  • Intervention Appropriateness [ Time Frame: Completed once within 2 weeks of exposure to the intervention ]

Central Contacts and Locations

Locations

University of Utah Medical Center

Recruiting

Salt Lake City, Utah, United States, 84112

Contacts

More Information

Sponsor

Michael Incze

Last update posted

Aug 10, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Michael Incze on 2026-08-10.